Douglas Lane & Associates LLC Sells 145,753 Shares of Haleon PLC Sponsored ADR $HLN

Douglas Lane & Associates LLC cut its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 2.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,546,637 shares of the company’s stock after selling 145,753 shares during the period. Douglas Lane & Associates LLC’s holdings in Haleon were worth $58,920,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of HLN. Public Employees Retirement System of Ohio lifted its holdings in Haleon by 136.4% in the 1st quarter. Public Employees Retirement System of Ohio now owns 222,708 shares of the company’s stock valued at $2,229,000 after purchasing an additional 128,493 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock worth $109,452,000 after buying an additional 1,586,230 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Haleon in the second quarter valued at approximately $1,186,000. Goodman Financial Corp purchased a new position in shares of Haleon during the first quarter valued at approximately $11,488,000. Finally, Milford Funds Ltd. purchased a new position in shares of Haleon during the fourth quarter valued at approximately $1,820,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HLN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Haleon in a research report on Tuesday, August 11th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Haleon Stock Up 0.4%

HLN stock traded up $0.04 during trading on Friday, reaching $9.29. The stock had a trading volume of 7,238,202 shares, compared to its average volume of 10,443,843. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The firm has a fifty day moving average price of $9.56 and a 200 day moving average price of $9.51. The company has a market capitalization of $40.88 billion, a P/E ratio of 23.83, a PEG ratio of 2.03 and a beta of 0.14. Haleon PLC Sponsored ADR has a 1-year low of $8.65 and a 1-year high of $11.28.

Haleon Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were paid a dividend of $0.0642 per share. This is a drop from Haleon’s previous dividend of $0.1307. The ex-dividend date was Friday, August 14th. This represents a yield of 132.0%. Haleon’s payout ratio is 30.77%.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.